KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Assets: 2018-2024

Historic Current Assets for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $360.2 million.

  • Castle Biosciences' Current Assets rose 3.71% to $357.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $357.6 million, marking a year-over-year increase of 3.71%. This contributed to the annual value of $360.2 million for FY2024, which is 21.82% up from last year.
  • Latest data reveals that Castle Biosciences reported Current Assets of $360.2 million as of FY2024, which was up 21.82% from $295.6 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' Current Assets registered a high of $429.6 million during FY2020, and its lowest value of $292.3 million during FY2022.
  • Its 3-year average for Current Assets is $316.0 million, with a median of $295.6 million in 2023.
  • In the last 5 years, Castle Biosciences' Current Assets surged by 268.18% in 2020 and then decreased by 17.66% in 2021.
  • Over the past 5 years, Castle Biosciences' Current Assets (Yearly) stood at $429.6 million in 2020, then dropped by 17.66% to $353.7 million in 2021, then fell by 17.37% to $292.3 million in 2022, then rose by 1.15% to $295.6 million in 2023, then grew by 21.82% to $360.2 million in 2024.